General Information of Drug (ID: DM0TDZI)

Drug Name
TAK-013 Drug Info
Synonyms
Sufugolix; TAK-013; 308831-61-0; UNII-56S17Z6X9M; CHEMBL22055; 56S17Z6X9M; TAK 013; Sufugolix [INN:BAN]; Sufugolix(TAK-013); SCHEMBL209021; GTPL1185; AC1MI503; DTXSID40184893; UCQSBGOFELXYIN-UHFFFAOYSA-N; MolPort-046-033-569; ZINC3842924; BDBM50122654; AKOS030629545; CS-6434; AS-35342; HY-100209; L001648; N-(4-(5-((benzyl(methyl)amino)methyl)-1-(2,6-difluorobenzyl)-1,2,3,4-tetrahydro-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea
Indication
Disease Entry ICD 11 Status REF
Uterine fibroids 2E86.0 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
3038517
CAS Number
CAS 308831-61-0
TTD Drug ID
DM0TDZI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gonadorelin DMAQ469 Amenorrhea GA20.0 Approved [3]
Relugolix DMK7IWL Prostate cancer 2C82.0 Approved [4]
Ganirelix DMGMB30 Ovulation dysfunction 5A80 Approved [5]
Abarelix DM5WFNP Prostate cancer 2C82.0 Approved [6]
Triptorelin DMTK4LS Infertility GB04 Approved [7]
Leuprorelin acetate DM15HAT Prostate cancer 2C82.0 Approved [8]
Nafarelin DMAHEFY Endometriosis GA10 Approved [9]
Cetrorelix DMFD9Q6 Ovarian stimulation LB45.1 Approved [10]
Elagolix sodium DMRDUC0 Endometriosis GA10 Approved [11]
Degarelix DM3O8QY Prostate cancer 2C82.0 Approved [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gonadotropin-releasing hormone receptor (GNRHR) TT8R70G GNRHR_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1185).
2 Non-peptide gonadotropin-releasing hormone receptor antagonists. J Med Chem. 2008 Jun 26;51(12):3331-48.
3 Use of cognitive behavior therapy for functional hypothalamic amenorrhea. Ann N Y Acad Sci. 2006 Dec;1092:114-29.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
5 Age attenuates testosterone secretion driven by amplitude-varying pulses of recombinant human luteinizing hormone during acute gonadotrope inhibiti... J Clin Endocrinol Metab. 2007 Sep;92(9):3626-32.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Regulation of GnRH I receptor gene expression by the GnRH agonist triptorelin, estradiol, and progesterone in the gonadotroph-derived cell line alphaT3-1. Endocrine. 2006 Aug;30(1):139-44.
8 Clinical pipeline report, company report or official report of Takeda (2009).
9 Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin ... Theriogenology. 2009 Apr 15;71(7):1037-45.
10 Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate. 2009 Jul 1;69(10):1025-33.
11 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
12 Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. J Med Chem. 2005 Jul 28;48(15):4851-60.